Loading...
Market
When will Brenus Pharma's precision cancer vaccine enter Phase 2 clinical trials?
2
Resolution / Starting Odds
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%
Official press release from Brenus Pharma or clinical trial registries
Story
Brenus Pharma Raises €22.2 Million ($25 Million) to Advance Cancer Vaccine Trials
Sep 19, 2024, 08:13 AM
Brenus Pharma, a French biotech company based in Lyon, has successfully raised €22.2 million ($25 million) in a Series A funding round. The funds will be used to accelerate the clinical trials of its precision cancer vaccines. The funding round was led by Angelor, a prominent investment firm. Brenus Pharma specializes in developing innovative cancer vaccines aimed at improving patient outcomes.
View original story
Similar markets
Yes • 50%
No • 50%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Yes • 50%
No • 50%
Less than €10M • 25%
Between €10M and €20M • 25%
Between €20M and €30M • 25%
More than €30M • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 or later • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Preclinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 or beyond • 25%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
Increases by more than 10% • 25%
Increases by 0-10% • 25%
Decreases by 0-10% • 25%
Decreases by more than 10% • 25%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%